Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection.

Bozzi A, Sayed N, Matsa E, Sass G, Neofytou E, Clemons KV, Correa-Oliveira R, Stevens DA, Wu JC.

Stem Cell Reports. 2019 Jun 11;12(6):1232-1241. doi: 10.1016/j.stemcr.2019.04.017. Epub 2019 May 16.

2.

Trends in US Emergency Department Visits for Pediatric Acute Ocular Injury.

Matsa E, Shi J, Wheeler KK, McCarthy T, McGregor ML, Leonard JC.

JAMA Ophthalmol. 2018 Aug 1;136(8):895-903. doi: 10.1001/jamaophthalmol.2018.2062. Erratum in: JAMA Ophthalmol. 2018 Aug 1;136(8):959.

3.

Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling.

Abilez OJ, Tzatzalos E, Yang H, Zhao MT, Jung G, Zöllner AM, Tiburcy M, Riegler J, Matsa E, Shukla P, Zhuge Y, Chour T, Chen VC, Burridge PW, Karakikes I, Kuhl E, Bernstein D, Couture LA, Gold JD, Zimmermann WH, Wu JC.

Stem Cells. 2018 Feb;36(2):265-277. doi: 10.1002/stem.2732. Epub 2017 Nov 13.

4.

A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

Comiskey DF Jr, Jacob AG, Sanford BL, Montes M, Goodwin AK, Steiner H, Matsa E, Tapia-Santos AS, Bebee TW, Grieves J, La Perle K, Boyaka P, Chandler DS.

Oncogene. 2018 Jan 4;37(1):95-106. doi: 10.1038/onc.2017.282. Epub 2017 Sep 11.

5.

Alloimmune Responses of Humanized Mice to Human Pluripotent Stem Cell Therapeutics.

Kooreman NG, de Almeida PE, Stack JP, Nelakanti RV, Diecke S, Shao NY, Swijnenburg RJ, Sanchez-Freire V, Matsa E, Liu C, Connolly AJ, Hamming JF, Quax PHA, Brehm MA, Greiner DL, Shultz LD, Wu JC.

Cell Rep. 2017 Aug 22;20(8):1978-1990. doi: 10.1016/j.celrep.2017.08.003.

6.

Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease.

Lin ZC, McGuire AF, Burridge PW, Matsa E, Lou HY, Wu JC, Cui B.

Microsyst Nanoeng. 2017 Mar 13;3:16080. doi: 10.1038/micronano.2016.80. eCollection 2017.

7.

A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell-Based Models for Cardiovascular Diseases.

Karakikes I, Termglinchan V, Cepeda DA, Lee J, Diecke S, Hendel A, Itzhaki I, Ameen M, Shrestha R, Wu H, Ma N, Shao NY, Seeger T, Woo N, Wilson KD, Matsa E, Porteus MH, Sebastiano V, Wu JC.

Circ Res. 2017 May 12;120(10):1561-1571. doi: 10.1161/CIRCRESAHA.116.309948. Epub 2017 Feb 28. Review.

8.

High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.

Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaaf2584. doi: 10.1126/scitranslmed.aaf2584.

9.

Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.

Matsa E, Burridge PW, Yu KH, Ahrens JH, Termglinchan V, Wu H, Liu C, Shukla P, Sayed N, Churko JM, Shao N, Woo NA, Chao AS, Gold JD, Karakikes I, Snyder MP, Wu JC.

Cell Stem Cell. 2016 Sep 1;19(3):311-25. doi: 10.1016/j.stem.2016.07.006. Epub 2016 Aug 18.

10.

Alternative approaches to generating cardiomyocytes are under development.

Chen IY, Matsa E, Wu JC.

Nat Rev Cardiol. 2016 Oct;13(10):574. doi: 10.1038/nrcardio.2016.130. Epub 2016 Aug 19. No abstract available.

PMID:
27538813
11.

Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.

Matsa E, Ahrens JH, Wu JC.

Physiol Rev. 2016 Jul;96(3):1093-126. doi: 10.1152/physrev.00036.2015. Review.

12.

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, Holmström A, Chang AC, Coronado MJ, Ebert AD, Knowles JW, Telli ML, Witteles RM, Blau HM, Bernstein D, Altman RB, Wu JC.

Nat Med. 2016 May;22(5):547-56. doi: 10.1038/nm.4087. Epub 2016 Apr 18.

13.

Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.

Chen IY, Matsa E, Wu JC.

Nat Rev Cardiol. 2016 Jun;13(6):333-49. doi: 10.1038/nrcardio.2016.36. Epub 2016 Mar 24. Review.

14.

Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.

Wu H, Lee J, Vincent LG, Wang Q, Gu M, Lan F, Churko JM, Sallam KI, Matsa E, Sharma A, Gold JD, Engler AJ, Xiang YK, Bers DM, Wu JC.

Cell Stem Cell. 2015 Jul 2;17(1):89-100. doi: 10.1016/j.stem.2015.04.020. Epub 2015 Jun 18.

15.

Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Burridge PW, Diecke S, Matsa E, Sharma A, Wu H, Wu JC.

Methods Mol Biol. 2016;1353:119-30. doi: 10.1007/7651_2015_196.

16.

Aberrant α-adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells.

Földes G, Matsa E, Kriston-Vizi J, Leja T, Amisten S, Kolker L, Kodagoda T, Dolatshad NF, Mioulane M, Vauchez K, Arányi T, Ketteler R, Schneider MD, Denning C, Harding SE.

Stem Cell Reports. 2014 Nov 11;3(5):905-14. doi: 10.1016/j.stemcr.2014.09.002. Epub 2014 Oct 11.

17.

Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform.

Sharma A, Marceau C, Hamaguchi R, Burridge PW, Rajarajan K, Churko JM, Wu H, Sallam KI, Matsa E, Sturzu AC, Che Y, Ebert A, Diecke S, Liang P, Red-Horse K, Carette JE, Wu SM, Wu JC.

Circ Res. 2014 Aug 29;115(6):556-66. doi: 10.1161/CIRCRESAHA.115.303810. Epub 2014 Jul 11.

18.

Chemically defined generation of human cardiomyocytes.

Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC.

Nat Methods. 2014 Aug;11(8):855-60. doi: 10.1038/nmeth.2999. Epub 2014 Jun 15.

19.

Human stem cells for modeling heart disease and for drug discovery.

Matsa E, Burridge PW, Wu JC.

Sci Transl Med. 2014 Jun 4;6(239):239ps6. doi: 10.1126/scitranslmed.3008921. Review.

20.

Oxidation of cellular amino acid pools leads to cytotoxic mistranslation of the genetic code.

Bullwinkle TJ, Reynolds NM, Raina M, Moghal A, Matsa E, Rajkovic A, Kayadibi H, Fazlollahi F, Ryan C, Howitz N, Faull KF, Lazazzera BA, Ibba M.

Elife. 2014 Jun 2;3. doi: 10.7554/eLife.02501.

21.

Cardiac stem cell biology: glimpse of the past, present, and future.

Matsa E, Sallam K, Wu JC.

Circ Res. 2014 Jan 3;114(1):21-7. doi: 10.1161/CIRCRESAHA.113.302895. Review.

22.

Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.

Matsa E, Dixon JE, Medway C, Georgiou O, Patel MJ, Morgan K, Kemp PJ, Staniforth A, Mellor I, Denning C.

Eur Heart J. 2014 Apr;35(16):1078-87. doi: 10.1093/eurheartj/eht067. Epub 2013 Mar 6.

23.

Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes.

Braam SR, Tertoolen L, Casini S, Matsa E, Lu HR, Teisman A, Passier R, Denning C, Gallacher DJ, Towart R, Mummery CL.

Stem Cell Res. 2013 Jan;10(1):48-56. doi: 10.1016/j.scr.2012.08.007. Epub 2012 Sep 7.

24.

Current status of drug screening and disease modelling in human pluripotent stem cells.

Rajamohan D, Matsa E, Kalra S, Crutchley J, Patel A, George V, Denning C.

Bioessays. 2013 Mar;35(3):281-98. doi: 10.1002/bies.201200053. Epub 2012 Aug 8. Review.

25.

In vitro uses of human pluripotent stem cell-derived cardiomyocytes.

Matsa E, Denning C.

J Cardiovasc Transl Res. 2012 Oct;5(5):581-92. Epub 2012 May 26. Review.

PMID:
22639342
26.

5-hydroxymethyl-cytosine enrichment of non-committed cells is not a universal feature of vertebrate development.

Almeida RD, Loose M, Sottile V, Matsa E, Denning C, Young L, Johnson AD, Gering M, Ruzov A.

Epigenetics. 2012 Apr;7(4):383-9. doi: 10.4161/epi.19375. Epub 2012 Apr 1.

PMID:
22419071
27.

Faster generation of hiPSCs by coupling high-titer lentivirus and column-based positive selection.

Dick E, Matsa E, Young LE, Darling D, Denning C.

Nat Protoc. 2011 Jun;6(6):701-14. doi: 10.1038/nprot.2011.320. Epub 2011 May 5.

PMID:
21637193
28.

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.

Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C.

Eur Heart J. 2011 Apr;32(8):952-62. doi: 10.1093/eurheartj/ehr073. Epub 2011 Mar 2.

29.

Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines.

Dick E, Matsa E, Bispham J, Reza M, Guglieri M, Staniforth A, Watson S, Kumari R, Lochmüller H, Young L, Darling D, Denning C.

Stem Cell Res. 2011 Mar;6(2):158-67. doi: 10.1016/j.scr.2010.10.002. Epub 2010 Nov 20.

30.

Feeder-free culture of human embryonic stem cells in conditioned medium for efficient genetic modification.

Braam SR, Denning C, Matsa E, Young LE, Passier R, Mummery CL.

Nat Protoc. 2008;3(9):1435-43. doi: 10.1038/nprot.2008.140.

PMID:
18772870

Supplemental Content

Support Center